ROIV Stock Nears Record High: Moderna Settlement Drives Q4 Profit, But Pipeline Catalysts Keep Retail Interested

• Roivant posted a net income of $355.7 million or $0.28 per share, compared to consensus estimates of a loss of $0.34, according to Fiscal.ai data.
• The bottom line was lifted by a $770.2 million gain related to a litigation settlement with Moderna.
• Unit Pulmovant expects to report topline Phase 2 data for treatment of pulmonary hypertension-associated interstitial lung disease in late 2026.

Shares of Roivant Sciences (ROIV) soared nearly 15% in pre-market trading on Wednesday, putting the stock on track for fresh record highs after the biotech firm delivered a fourth-quarter profit and unveiled promising milestone updates across its autoimmune disease pipeline.

ROIV shares are on track to reverse a three-session losing streak and could also clock their biggest single-day gains in over three months if they close above $9.

ROIV’s Key Milestones Coming Up This Year

Roivant Sciences and its subsidiaries outlined several upcoming clinical and regulatory milestones across their autoimmune and pulmonary disease programs.

Priovant expects to launch Brepocitinib for dermatomyositis by the end of September 2026 after the U.S. Food and Drug Administration (FDA) accepted the drug’s New Drug Application (NDA) with Priority Review. The company also plans to begin a Phase 3 study in cutaneous sarcoidosis in the second half of 2026.

Meanwhile, Immunovant plans to provide updates on IMVT-1402 in rheumatoid arthritis and report topline data in cutaneous lupus erythematosus (chronic autoimmune disease) during the second half of 2026. Pulmovant expects to report topline Phase 2 data for Mosliciguat in pulmonary hypertension-associated interstitial lung disease in late 2026.

Moderna Litigation Windfall Drives Q4 Bottomline

Roivant Sciences recorded a $770.2 million gain related to a litigation settlement involving its subsidiary Genevant Sciences. The payment is part of a larger $2.25 billion agreement under which Moderna (MRNA) agreed to settle claims tied to the use of lipid nanoparticle technology in its COVID-19 vaccines.

The settlement helped Roivant post net income of $355.7 million for the quarter, compared with a loss of $252.4 million a year earlier. Earnings per share came in at $0.28, compared to consensus estimates of a loss of $0.34, according to fiscal.ai data.

Retail Sees ROIV Breaking Out

Retail sentiment for ROIV on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.

One user highlighted a breakout.

The stock has gained around 28% so far this year.

Read also: KEYS Surges Into Spotlight After Q2 Beat: Analysts See More AI Upside, Retail Sees Run Toward $400

For updates and corrections, email newsroom[at]stocktwits[dot]com.